Walvax BioTech (300142) — Working Capital to Net Assets Ratio
Walvax BioTech (300142) has a Working Capital to Net Assets ratio of 29.8% as of March 2026. Working capital of CN¥2.33 Billion (current assets of CN¥4.33 Billion minus current liabilities of CN¥2.00 Billion) is measured against net assets of CN¥7.81 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 300142 equity to assets ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Walvax BioTech Working Capital to Net Assets (2007–2025)
This chart shows how Walvax BioTech's Working Capital to Net Assets ratio has evolved across 19 annual periods from 2007 to 2025. As of March 2026, the ratio stands at 29.8%, reflecting working capital of CN¥2.33 Billion against net assets of CN¥7.81 Billion CNY. Check Walvax BioTech tangible book value ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Walvax BioTech (2007–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Walvax BioTech from 2007 to 2025, covering 19 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 300142 stock market capitalisation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 26.6% | CN¥2.61 Billion | CN¥9.81 Billion | CN¥4.55 Billion | CN¥1.94 Billion | ▼ -14.2 pp |
| 2024 | 40.8% | CN¥4.70 Billion | CN¥11.51 Billion | CN¥7.07 Billion | CN¥2.37 Billion | ▼ -7.7 pp |
| 2023 | 48.5% | CN¥5.53 Billion | CN¥11.40 Billion | CN¥8.73 Billion | CN¥3.20 Billion | ▼ -1.0 pp |
| 2022 | 49.5% | CN¥5.44 Billion | CN¥10.99 Billion | CN¥8.95 Billion | CN¥3.51 Billion | ▲ +5.0 pp |
| 2021 | 44.5% | CN¥4.44 Billion | CN¥10.00 Billion | CN¥7.68 Billion | CN¥3.24 Billion | ▲ +1.8 pp |
| 2020 | 42.7% | CN¥3.35 Billion | CN¥7.85 Billion | CN¥4.78 Billion | CN¥1.43 Billion | ▲ +1.1 pp |
| 2019 | 41.6% | CN¥2.36 Billion | CN¥5.67 Billion | CN¥3.44 Billion | CN¥1.09 Billion | ▼ -7.9 pp |
| 2018 | 49.5% | CN¥2.60 Billion | CN¥5.26 Billion | CN¥4.14 Billion | CN¥1.54 Billion | ▲ +27.8 pp |
| 2017 | 21.7% | CN¥771.37 Million | CN¥3.56 Billion | CN¥2.25 Billion | CN¥1.48 Billion | ▼ -8.1 pp |
| 2016 | 29.8% | CN¥1.05 Billion | CN¥3.52 Billion | CN¥3.03 Billion | CN¥1.98 Billion | ▲ +23.9 pp |
| 2015 | 5.9% | CN¥179.12 Million | CN¥3.02 Billion | CN¥2.37 Billion | CN¥2.19 Billion | ▼ -19.1 pp |
| 2014 | 25.1% | CN¥805.31 Million | CN¥3.21 Billion | CN¥2.22 Billion | CN¥1.42 Billion | ▼ -2.6 pp |
| 2013 | 27.6% | CN¥811.79 Million | CN¥2.94 Billion | CN¥2.69 Billion | CN¥1.88 Billion | ▼ -15.5 pp |
| 2012 | 43.1% | CN¥1.37 Billion | CN¥3.17 Billion | CN¥2.39 Billion | CN¥1.02 Billion | ▼ -39.0 pp |
| 2011 | 82.2% | CN¥2.23 Billion | CN¥2.71 Billion | CN¥2.50 Billion | CN¥268.70 Million | ▼ -7.0 pp |
| 2010 | 89.2% | CN¥2.28 Billion | CN¥2.55 Billion | CN¥2.61 Billion | CN¥331.09 Million | ▲ +14.5 pp |
| 2009 | 74.7% | CN¥130.44 Million | CN¥174.69 Million | CN¥234.61 Million | CN¥104.17 Million | ▲ +95.4 pp |
| 2008 | -20.7% | CN¥-20.35 Million | CN¥98.36 Million | CN¥171.06 Million | CN¥191.41 Million | ▲ +438.6 pp |
| 2007 | -459.3% | CN¥-81.10 Million | CN¥17.66 Million | CN¥102.70 Million | CN¥183.80 Million | — |